Calls Now Open

2026 Scholar-Innovator, Harrington Prize and ADDF-Harrington

You've just added:

Home / News

News + Media

April 29, 2025

Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council

Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation Continue Reading

April 16, 2025

Harrington Discovery Institute Opens Call for 2026 Harrington Scholar-Innovator Award

Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading

March 19, 2025

International Harrington Prize Awarded to Dr. Owen Witte

2025 Harrington Prize for Innovation in Medicine recognizes groundbreaking contributions in the creation of targeted cancer therapies Continue Reading

February 18, 2025

Top Neuroscientist Matthew Anderson Appointed Co-Director of the Oxford-Harrington Rare Disease Centre

Renowned US Neuroscientist and Harvard Professor brings extensive expertise in academia and industry to advance rare disease research Continue Reading

February 05, 2025

Synergy for Change Award to Morgan Stanley GIFT and Harrington Discovery Institute

Award highlights collaboration between for profit and non-profit achieving great impact Continue Reading

January 15, 2025

Oxford-Harrington Rare Disease Centre Opens 2025 Call for Proposals

Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading

January 13, 2025

2023-2024 Harrington Annual Publication

Next Generation Medicines Continue Reading

December 03, 2024

AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Continue Reading

November 15, 2024

AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Oxford, UK – 15th November 2024 – (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes using inhaled gene therapy, announces that it has been granted a Rare Pediatric Disease Designation (RPDD) by the US Food & Drug Administration (FDA) for AVG-002, its novel... Continue Reading

October 24, 2024

The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare Disease Scholar Award Recipients

10 scientists have been selected for OHC’s first annual award to advance academic discoveries into clinical practice for rare diseases Continue Reading

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.